Lexicon Pharmaceuticals (LXRX)
(Delayed Data from NSDQ)
$2.39 USD
+0.06 (2.58%)
Updated Jul 26, 2024 04:00 PM ET
After-Market: $2.38 -0.01 (-0.42%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth C Momentum F VGM
Brokerage Reports
0 items in cart
Lexicon Pharmaceuticals, Inc. [LXRX]
Reports for Purchase
Showing records 381 - 396 ( 396 total )
Company: Lexicon Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
LX1033 Data To Be Presented at DDW Confirms Potency and Biomarker Utility
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Lexicon Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Q1 Financials In Line; Next Value-Driver: Phase 2 LX4211 Data Release in late June; Reiterate OUTPERFORM
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Lexicon Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
We Anticipate Phase 2b LX4211 Data Release At The End Of Q2 As The Next Major Value-Driver . Reiterate OUTPERFORM.
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Lexicon Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Emerging Pharmaceuticals -Q2 2012 Catalysts for Emerging Pharmaceuticals
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Lexicon Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Q4 Financials Highlight Near-Term Catalysts Including Phase 2 LX4211 Data Release in Mid-2012. Reiterate OUTPERFORM.
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Lexicon Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
LIFE SCIENCES: The Week Ahead in Life Sciences - Upcoming Events for the Week of February 12
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Lexicon Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Lexicon Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Pioneers Get the Arrows: We Believe LX4211 Will Have Smoother Sailing With the FDA Than Dapagliflozin. Reiterate OUTPERFORM and $3 Fair Value
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Lexicon Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Phase 2a LX2931/Rheumatoid Arthritis Data Presented at ACR Confirms Safety
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Lexicon Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Q3 Financials Slightly Better Than Consensus. Telotristat Etiprate (LX1032) Near-Term Partnership Could Be Value- Driver
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Lexicon Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Mechanistic Results at EASD Strengthen Its Profile for Diabetes and Cardiovascular Disease
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Lexicon Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Q2 Financials In-Line. Telotristat Etiprate (LX1032) Showed Efficacy Signals In Phase 2a.
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Lexicon Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Lexicon Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Lexicon Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Q1 Financials Not Material In Our View. We Anticipate Clinical Catalyst In Q3.
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Lexicon Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Initiating Coverage of LXRX With an OUTPERFORM Rating and Fair Value of $3. Multiple Shots on Goal Reduces Pipeline Risk, in our View
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L